黄芪颗粒联合普米克令舒对哮喘患儿急性发作期嗜酸性粒细胞及肺功能的影响

Effect of Huangqikeli Combined with Budesonide Suspension for Inhalation on Eosinophils and Lung Function in Children with Asthma during Acute Attack

目的探讨黄芪颗粒联合普米克令舒对哮喘患儿急性发作期嗜酸性粒细胞(EOS)及肺功能的影响。方法选取急性发作期哮喘患儿86例,依据随机数字表法分为观察组和对照组,各43例。对照组采用雾化吸入普米克令舒治疗,观察组在对照组基础上给予黄芪颗粒治疗。检测2组治疗前后EOS、免疫球蛋白E(IgE)、白细胞介素4(IL-4)、干扰素γ(IFN-γ)水平。比较2组治疗前后肺功能的变化,包括呼气峰值流速(PEF)、呼气峰流量(PEER)、第一秒用力呼气量(FEV1)。结果观察组总有效率(95.35%)高于对照组(81.40%),差异有统计学意义(P<0.05)。治疗前,2组EOS、IgE、IL-4、IFN-γ、PEF、PEER、FEV1水平比较,差异无统计学意义(P>0.05);治疗后,观察组EOS、IgE、IL-4水平[(4.72±1.16)%,(63.15±14.97)IU·mL^(-1),(198.41±39.56)ng·L^(-1)]低于对照组[(6.51±1.40)%,(78.42±16.25)IU·mL^(-1),(254.30±43.57)ng·L^(-1)],IFN-γ水平(138.42±32.91)ng·L^(-1),高于对照组(119.54±29.26)ng·L^(-1),差异有统计学意义(P<0.05);治疗后观察组PEF、PEER、FEV1水平[(195.03±25.13)L·min^(-1),(2.83±0.27)%,(2.38±0.42)L]高于对照组[(179.36±23.27)L·min^(-1),(2.56±0.31)%,(2.07±0.38)L],差异有统计学意义(P<0.05)。结论黄芪颗粒联合普米克令舒能显著降低急性发作哮喘患儿EOS水平,改善肺功能。

Objective To investigate the effects of Huangqikeli combined with Budesonide Suspension for Inhalation on eosinophils(EOS)and lung function in children with asthma during acute attack.Methods A total of 86 children with acute asthma were selected and divided into observation group and control group according to the random number table method,with 43 cases in each group.The control group was treated with nebulized inhalation of Budesonide Suspension for Inhalation,and the observation group was treated with Huangqi granules on the basis of the control group.The levels of EOS,immunoglobulin E(IgE),interleukin 4(IL-4)and interferonγ(IFN-γ)were detected before and after treatment in the two groups.The changes of lung function before and after treatment were compared between the two groups,including peak expiratory flow(PEF),peak expiratory flow(PEER),and forced expiratory volume in the first second(FEV1).Results The total effective rate of the observation group(95.35%)was higher than that of the control group(81.40%),and the difference was statistically significant(P<0.05).Before treatment,the two groups of EOS,IgE,IL-4,IF-γ,PEF,PEER,FEV1 levels were not statistically different(P>0.05);after treatment,the observation group EOS,IgE,IL-4 levels[(4.72±1.16)%,(63.15±14.97)IU·mL^(-1),(198.41±39.56)ng·L^(-1)]lower than the control group[(6.51±1.40)%,(78.42±16.25)IU·mL^(-1),254.30±43.57)ng·L^(-1),IFN-γlevel(138.42±32.91)ng·L^(-1),higher than the control group(119.54±29.26)ng·L^(-1),the difference was statistically significant(P<0.05);PEF,PEER,FEV1 levels in the observation group after treatment[(195.03±25.13)L·min^(-1),(2.83±0.27)%,(2.38±0.42)L]higher than the control group[(179.36±23.27)L·min^(-1),(2.56±0.31)%,(2.07±0.38)L],the difference was statistically significant(P<0.05).Conclusion Astragalus granules combined with Budesonide Suspension for Inhalation can significantly reduce the level of EOS in children with acute asthma and improve lung function.